Rezdifra is a novel targeted therapy drug, but specific information about the drug is currently not provided in search results. According to the existing information, the search results mainly include detailed information on other anti-cancer drugs such as riptinib, remitinib, and lubitidine, as well as insomnia treatment drugs, but do not involve relevant content on rosmertinib.

1. Relevant drug information

(1) Riptinib: a second-generation tyrosine kinase inhibitor used for the treatment of ROS1 positive non-small cell lung cancer and NTRK positive solid tumors. It was approved in the United States in 2023 and entered the Chinese market in 2024.

(2) Remdesidine: a melatonin receptor agonist used to treat insomnia with difficulty falling asleep. It was approved in the United States in 2005 and has not yet been marketed in China.

(3) Rubicitidine: a marine derived RNA polymerase inhibitor used for the treatment of solid tumors with specific genetic characteristics, possessing a unique DNA binding mechanism.

2 Trends in drug development

(1) Targeted therapy: Currently, the development of anti-tumor drugs mainly focuses on specific gene mutations or protein targets, such as ROS1, NTRK, etc.

(2) Precision medicine: The new generation of drugs emphasizes individualized treatment strategies based on molecular subtyping, such as lapatinib targeting EGFR mutation patients.

(3) Combination therapy: Drug development tends to explore combination therapy regimens, such as targeting the MEK signaling pathway with bimetinib.